Comparative Pharmacology
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus OMNICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus OMNICEF.
CEFPODOXIME PROXETIL vs OMNICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
200 mg orally every 12 hours
300 mg orally twice daily for 10 days; or 600 mg orally once daily for 10 days (for community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, uncomplicated skin infections).
None Documented
None Documented
Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min).
1.7 hours (range 1.2–2.3 h) in healthy adults; prolonged to 3.2–6.6 h in renal impairment (CrCl <30 mL/min); no significant change in hepatic impairment.
Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days.
Renal excretion as unchanged drug: 80-90% (primarily via glomerular filtration and tubular secretion); biliary/fecal: 10-20% (minor).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic